These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29394358)

  • 1. Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up.
    Yu MC; Chiang CY; Lee JJ; Chien ST; Lin CJ; Lee SW; Lin CB; Yang WT; Wu YH; Huang YW
    Clin Infect Dis; 2018 Jul; 67(2):202-210. PubMed ID: 29394358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan.
    Lee PH; Chan PC; Peng YT; Chu PW; Wu MH; Jou R; Yu MC; Lin CJ; Huang YW; Chien ST; Lee JJ; Chiang CY
    PLoS One; 2019; 14(4):e0214792. PubMed ID: 30939150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study.
    Chan PC; Huang SH; Yu MC; Lee SW; Huang YW; Chien ST; Lee JJ;
    PLoS One; 2013; 8(2):e57719. PubMed ID: 23451263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study.
    Chiang SS; Starke JR; Miller AC; Cruz AT; Del Castillo H; Valdivia WJ; Tunque G; García F; Contreras C; Lecca L; Alarcón VA; Becerra MC
    Clin Infect Dis; 2016 Oct; 63(8):1063-71. PubMed ID: 27458026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
    Jaber AAS; Ibrahim B
    BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
    Kibret KT; Moges Y; Memiah P; Biadgilign S
    Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
    Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
    J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.
    Mulu W; Mekonnen D; Yimer M; Admassu A; Abera B
    Afr Health Sci; 2015 Jun; 15(2):368-77. PubMed ID: 26124781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.
    Anderson LF; Tamne S; Watson JP; Cohen T; Mitnick C; Brown T; Drobniewski F; Abubakar I
    Euro Surveill; 2013 Oct; 18(40):. PubMed ID: 24128699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes is associated with drug-resistant tuberculosis in Eastern Taiwan.
    Hsu AH; Lee JJ; Chiang CY; Li YH; Chen LK; Lin CB
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):354-6. PubMed ID: 23228433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.